Summary of clinical experience with recombinant factor VIII products — Kogenate J. M. Lusher OriginalPaper Pages: S3 - S6
Summary of clinical experience with recombinant factor VIII products — Recombinate G. C. White II OriginalPaper Pages: S7 - S8
Design and operation of a recombinant mammalian cell manufacturing process for rFVIII R. Adamson OriginalPaper Pages: S9 - S14
Cell culture and purification process — purity and safety testing H. M. Koplove OriginalPaper Pages: S15 - S20
Recombinate: viral safety and final product manufacturing testing and specifications J. Lawrence OriginalPaper Pages: S21 - S24
Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII G. Bray OriginalPaper Pages: S29 - S34
Case report of an inhibitor patient treated with recombinant factor VIII H. Kim OriginalPaper Pages: S37 - S37
A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII D. Brettler OriginalPaper Pages: S49 - S50
Stability of factor VIII preparation in continuous infusion U. Martinowitz OriginalPaper Pages: S69 - S71
Strategies and mechanisms for long-term surveillance of inhibitor patients D. DiMichele OriginalPaper Pages: S75 - S77
Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients — antibodies and reactions J. Ingerslev OriginalPaper Pages: S79 - S80
Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients — non-human viral transmission J. S. Robertson OriginalPaper Pages: S81 - S82
Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients — impact on the immune and other systems M. -C. Poon OriginalPaper Pages: S83 - S86
Long-term surveillance of HIV, HBV, and HCV infected patients A. Shapiro OriginalPaper Pages: S87 - S88
